Citadel Advisors’s Kyverna Therapeutics KYTX Stock Holding History

Citadel Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-38,500	Closed	-$362K	–	14442
2025 Q4	$362K	Buy	+38,500	New	+$286K	﹤0.01%	9744
2025 Q2	–	Sell	-1,600	Closed	-$3.09K	–	15476
2025 Q1	$3.09K	Sell	1,600 -1,200	-43%	-$3.55K	﹤0.01%	13987
2024 Q4	$10.5K	Sell	2,800 -11,000	-80%	-$52.7K	﹤0.01%	13600
2024 Q3	$67.5K	Buy	13,800 +200	+1%	+$1.54K	﹤0.01%	11602
2024 Q2	$102K	Buy	13,600 +6,300	+86%	+$96.3K	﹤0.01%	10888
2024 Q1	$181K	Buy	+7,300	New	+$204K	﹤0.01%	10478

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Citadel Advisors's KYTX Position: Q1 2026 in Review

Citadel Advisors reduced its Kyverna Therapeutics (KYTX) stake by 79% in Q1 2026, selling an estimated $1.81M and leaving 58,126 shares worth $502K. The position accounts for ﹤0.01% of the portfolio, ranked #9303.

Citadel Advisors first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $13M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

Citadel Advisors held 58,126 shares of Kyverna Therapeutics worth $502K as of Q1 2026.
Citadel Advisors sold 217,320 Kyverna Therapeutics shares in Q1 2026, an estimated $1.81M.
Kyverna Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9303 holding.
Citadel Advisors first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
Citadel Advisors's Kyverna Therapeutics position peaked at $13M in Q1 2024.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.